Financial and investor relations calendar for 2009
Innate Pharma SA announces its tentative financial and investor relations calendar for 2009.
Financials and Corporate
Vivalis and Innate Pharma sign a collaboration and commercial license agreement
Vivalis and Innate Pharma sign a collaboration and commercial license agreement to develop Innate's novel monoclonal antibody, to be manufactured with Vivalis' EB66® platform, for rare cutaneous...
Financial results for 2008
Innate Pharma SA reports today its financial results for 2008: stable operational expenses and expanded R&D portfolio.
Milestone payment in IPH 24 project developed in collaboration with Novo Nordisk A/S
Innate Pharma SA announces the achievement of a milestone payment in a new monoclonal antibody project developed in collaboration with Novo Nordisk A/S.
Operating revenue of 12.9 million Euros for the year 2008
Innate Pharma SA today announces an operating revenue of 12.9 million Euros for the year 2008. Turnover for the year amounted to 7.5 million Euros, including 1.6 million Euros in the fourth quarter...